Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 2/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10177563 | 0.97 | HTT (0.47) | HTTLMNASMN1; SMN2MAPTSYK | |
| SCHEMBL20970467 | 0.96 | HTT (0.47) | HTTLMNASMN1; SMN2MAPTSYK | |
| SCHEMBL18879474 | 0.96 | MAPT (0.48) | HTTLMNASMN1; SMN2MAPTSYK | |
| SCHEMBL16250387 | 0.93 | HTT (0.44) | HTTLMNASMN1; SMN2MAPTSYK | |
| SCHEMBL5130258 | 0.93 | SYK (0.48) | HTTLMNASMN1; SMN2MAPTSYK | |
| SCHEMBL17236092 | 0.93 | HTT (0.43) | HTTLMNASMN1; SMN2MAPTSYK | |
| SCHEMBL16846736 | 0.92 | MAPT (0.43) | HTTLMNASMN1; SMN2MAPTSYK | |
| SCHEMBL24383295 | 0.89 | LMNA (0.63) | HTTLMNASMN1; SMN2MAPTSYK | |
| SCHEMBL18705411 | 0.89 | CYP3A4 (0.43) | HTTLMNASMN1; SMN2MAPTSYK | |
| SCHEMBL20904164 | 0.88 | CYP3A4 (0.46) | HTTLMNASMN1; SMN2MAPTSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605451-B2 | Targeted plasma protein degradation | NOVARTIS AG (CH) | 2026-04-21 | — | — | US | disclosed |
| US-20240309084-A1 | DEGRADATION OF EXTRACELLULAR TARGETS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-09-19 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| EP-4281115-A1 | DEGRADATION OF EXTRACELLULAR TARGETS | Novartis AG (CH) | 2023-11-29 | — | — | EP | disclosed |
| EP-4100064-A1 | TARGETED PLASMA PROTEIN DEGRADATION | Novartis AG (CH) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022157626-A1 | DEGRADATION OF EXTRACELLULAR TARGETS | NOVARTIS AG (CH) | 2022-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240309084-A1 | DEGRADATION OF EXTRACELLULAR TARGETS | MMP12, ENGASE, MMP8 | HTT 2847/4885LMNA 1963/4885SMN1; SMN2 3190/4885 |
| US-12605451-B2 | Targeted plasma protein degradation | M6PR, ASGR1, IGF2R | HTT 3084/4885LMNA 1051/4885SMN1; SMN2 2925/4885 |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | M6PR, ASGR1, IGF2R | HTT 3382/4885LMNA 2133/4885SMN1; SMN2 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.